RYET to Enter Malaysian Healthcare Through Exclusive Cogni AI License to BioNexus Gene Lab
BGLC signed a definitive agreement for an exclusive 10-year license (extendable to 20 years) of RYET's Cogni AI platform for healthcare in Malaysia, with a 10% royalty to RYET and the right to expand into other Malaysian industries. BGLC would pay US$3.5 million in license consideration via 410,000 shares (quoted value US$520,700 at Oct 2 closes) and issue 150,000 additional shares in a reciprocal exchange for 500,000 RYET shares. The deal has not closed: it requires BGLC acceptance testing, due diligence, regulatory approvals, and a PRC export license RYET has not obtained, and either party may terminate if closing has not occurred by March 31, 2027.
Key figures
- Deal Value Usd
- $3.5 million
- Shares Offered
- 560000
- License term
- 10 years, renewable for two 5-year terms (up to 20 years)
- Royalty rate
- 10%
- Liability cap
- $1,000,000
- Bglc close price oct2
- US$1.27
- Ryet close price oct2
- US$0.8599
- Exchange shares to ryet
- 150000
- License shares quoted value
- $520,700
- Exchange shares quoted value
- $190,500
- License consideration shares
- 410000
- Ryet shares received by ryet
- 500000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.